1. Report Overview
1.1 Introduction to Molecular Diagnostics Market
1.2 Molecular Diagnostics Market Definition
1.3 Why You Should Read This Report
1.4 What This Report Delivers
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 COVID-19 Impact: Recovery Scenarios
1.7.2 Market Evaluation & Forecasting Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Dynamics
3.1 Drivers
3.1.1 Growing Geriatric Population Base
3.1.2 Increase in Demand for Point-of-Care Facilities
3.1.3 Growing Prevalence of Target Diseases Such as Genetic, CVDs, Neurological Diseases etc.
3.2 Restraints
3.2.1 High Prices of Molecular Diagnostics Tests
3.2.2 Presence of Ambiguous Regulatory Framework to Impede Market Growth
3.3 Opportunities
3.3.1 Technological Advancements to Pave Way for Fresh Revenue Pockets
3.3.2 Growing Demand from Emerging Economies to Offer Lucrative Growth Opportunities
3.3.3 Increase in the Adoption of Automation and Multiplexing of Technologies
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weaknesses
3.4.3 Opportunities
3.4.4 Threats
3.5 Industry analysis – Porter’s
3.5.1 Buyer Power
3.5.2 Supplier Power
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitute
3.5.5 Threat of New Entrants
3.6 Industry analysis – PEST Analysis
3.6.1 Political Factors Impacting Molecular Diagnostics Market
3.6.2 Economic Factors Impacting Molecular Diagnostics Market
3.6.3 Social Factors Impacting Molecular Diagnostics Market
3.6.4 Technological Factors Impacting Molecular Diagnostics Market
4 North America Molecular Diagnostics Market by Technology
4.1 Polymerase Chain Reaction Segment Market Forecast, 2021-2031
4.1.1 Technological Advancements to Fuel PCR Segment Growth
4.1.2 Polymerase Chain Reaction Market by Sub-Segment, 2021-2031
4.1.3 Recovery Scenarios (V, U, W, L)
4.2 In Situ Hybridization Segment Market Forecast, 2021-2031
4.2.1 Increasing Incidence of Genetic Disorder and Cancer to Boost ISH Market Growth
4.2.2 Recovery Scenarios (V, U, W, L)
4.3 Isothermal Nucleic Acid Amplification Technology Segment Market Forecast, 2021-2031
4.3.1 Rising Prevalence of Infectious Disease to Drive INAAT Market Growth
4.3.2 Recovery Scenarios (V, U, W, L)
4.4 Chips and Microarrays Segment Market Forecast, 2021-2031
4.4.1 Increasing Usage in Basic Molecular Biology to Drive Segmental Growth
4.4.2 Recovery Scenarios (V, U, W, L)
4.5 Mass Spectrometry Segment Market Forecast, 2021-2031
4.5.1 Multidimensional Analysis and Evaluation of Impurities During Drug Development Process Fuelling Market Growth
4.5.2 Recovery Scenarios (V, U, W, L)
4.6 Sequencing Segment Market Forecast, 2021-2031
4.6.1 Sequencing Segment to Offer Massive Advances in Diagnosis, Prognosis and Treatment of Disease
4.6.2 Recovery Scenarios (V, U, W, L)
4.7 Transcription Mediated Amplification Segment Market Forecast, 2021-2031
4.7.1 Recovery Scenarios (V, U, W, L)
4.8 Others Segment Market Forecast, 2021-2031
4.8.1 Recovery Scenarios (V, U, W, L)
5 North America Molecular Diagnostics Market by Application
5.1 Oncology Segment Market Forecast, 2021-2031
5.1.1 Rising Prevalence of Cancer to Propel Market Growth
5.1.2 Oncology Market by Sub-Segment, 2021-2031
5.1.3 Recovery Scenarios (V, U, W, L)
5.2 Pharmacogenomics Segment Market Forecast, 2021-2031
5.2.1 Increasing Importance Across Emerging Economies to Fuel Pharmacogenomics Market Growth
5.2.2 Recovery Scenarios (V, U, W, L)
5.3 Infectious Diseases Segment Market Forecast, 2021-2031
5.3.1 Technological Advancements to Propel Usage of Molecular Diagnostics for Infectious Diseases
5.3.2 Infectious Diseases Market by Sub-Segment, 2021-2031
5.3.3 Recovery Scenarios (V, U, W, L)
5.4 Genetic Testing Segment Market Forecast, 2021-2031
5.4.1 Genetic Testing Has Led to Expansion of Molecular Techniques Withing Clinical Laboratories
5.4.2 Genetic Testing Market by Sub-Segment, 2021-2031
5.4.3 Recovery Scenarios (V, U, W, L)
5.5 Neurological Disease Segment Market Forecast, 2021-2031
5.5.1 Molecular Diagnostics for Infectious Diseases to Witness Significant Growth
5.5.2 Recovery Scenarios (V, U, W, L)
5.6 Cardiovascular Diseases Segment Market Forecast, 2021-2031
5.6.1 Growing Burden of CVDs Across Emerging Economies to Fuel Segmental Market Growth
5.6.2 Recovery Scenarios (V, U, W, L)
5.7 Microbiology Segment Market Forecast, 2021-2031
5.7.1 Technological Advancements Fuelling Microbiology Segment Growth
5.7.2 Recovery Scenarios (V, U, W, L)
5.8 Others Segment Market Forecast, 2021-2031
5.8.1 Recovery Scenarios (V, U, W, L)
6 North America Molecular Diagnostics Market by Product
6.1 Instruments Segment Market Forecast, 2021-2031
6.1.1 Strong Demand from Emerging Economies for Advanced Instruments
6.1.2 Recovery Scenarios (V, U, W, L)
6.2 Reagents Segment Market Forecast, 2021-2031
6.2.1 Reagents Segment Accounts for Majority of the Market Share
6.2.2 Recovery Scenarios (V, U, W, L)
7 North America Molecular Diagnostics Market by Test Location
7.1 Point-of-Care Segment Market Forecast, 2021-2031
7.1.1 Recovery Scenarios (V, U, W, L)
7.2 Over the Counter Segment Market Forecast, 2021-2031
7.2.1 Recovery Scenarios (V, U, W, L)
7.3 Central Laboratories Segment Market Forecast, 2021-2031
7.3.1 Recovery Scenarios (V, U, W, L)
8 North America Molecular Diagnostics Market by Country
8.1 Largest Molecular Diagnostics Market Globally
8.2 North America Molecular Diagnostics Market by Country, Forecast 2021-2031
8.3 U.S. Molecular Diagnostics Market Forecast by Technology
8.3.1 Recovery Scenarios (V, U, W, L)
8.4 U.S. Molecular Diagnostics Market Forecast by Application
8.4.1 Recovery Scenarios (V, U, W, L)
8.5 U.S. Molecular Diagnostics Market Forecast by Product
8.5.1 Recovery Scenarios (V, U, W, L)
8.6 U.S. Molecular Diagnostics Market Forecast by Test Location
8.6.1 Recovery Scenarios (V, U, W, L)
8.7 U.S. Molecular Diagnostics Market Forecast, 2021-2031
8.7.1 U.S. Accounts for Majority of the North American Molecular Diagnostics Market
8.7.2 Recovery Scenarios (V, U, W, L): U.S. Molecular Diagnostics Market Forecast, 2021-2031
8.8 Canada Molecular Diagnostics Market Forecast by Technology
8.8.1 Recovery Scenarios (V, U, W, L)
8.9 Canada Molecular Diagnostics Market Forecast by Application
8.9.1 Recovery Scenarios (V, U, W, L)
8.10 Canada Molecular Diagnostics Market Forecast by Product
8.10.1 Recovery Scenarios (V, U, W, L)
8.11 Canada Molecular Diagnostics Market Forecast by Test Location
8.11.1 Recovery Scenarios (V, U, W, L)
8.12 Canada Molecular Diagnostics Market Forecast, 2021-2031
8.12.1 Rising Investments by Government to Spur Regional Market Growth
8.12.2 Recovery Scenarios (V, U, W, L): Canada Molecular Diagnostics Market Forecast, 2021-2031
9 Company Profiles
9.1 Roche Diagnostics
9.1.1 Company Snapshot
9.1.2 Company Overview
9.1.3 Financial Analysis
9.1.3.1 Net Revenue, 2015-2019
9.1.3.2 R&D Expenses, 2015-2019
9.1.3.3 Gross Profit, 2015-2019
9.1.3.4 Net Income, 2015-2019
9.1.3.5 EBDITA, 2015-2019
9.1.4 Product Benchmarking
9.1.5 Recent Developments, 2017-2020
9.2 Abbott
9.2.1 Company Snapshot
9.2.2 Company Overview
9.2.3 Financial Analysis
9.2.3.1 Net Revenue, 2015-2019
9.2.3.2 R&D Expenses, 2015-2019
9.2.3.3 Gross Profit, 2015-2019
9.2.3.4 Net Income, 2015-2019
9.2.3.5 EBDITA, 2015-2019
9.2.4 Product Benchmarking
9.3 Becton, Dickinson and Company
9.3.1 Company Snapshot
9.3.2 Company Overview
9.3.3 Financial Analysis
9.3.3.1 Net Revenue, 2015-2020
9.3.3.2 R&D Expenses, 2015-2020
9.3.3.3 Gross Profit, 2015-2020
9.3.3.4 Net Income, 2015-2020
9.3.3.5 EBDITA, 2015-2020
9.3.4 Product Benchmarking
9.3.5 Recent Developments, 2017-2020
9.4 bioMérieux SA
9.4.1 Company Snapshot
9.4.2 Company Overview
9.4.3 Financial Analysis
9.4.3.1 Net Revenue, 2016-2019
9.4.3.2 R&D Expenses, 2015-2019
9.4.3.3 Gross Profit, 2015-2019
9.4.3.4 Net Income, 2016-2019
9.4.3.5 EBDITA, 2015-2019
9.4.4 Product Benchmarking
9.4.5 Recent Developments, 2017-2020
9.5 Bio-Rad Laboratories, Inc.
9.5.1 Company Snapshot
9.5.2 Company Overview
9.5.3 Financial Analysis
9.5.3.1 Net Revenue, 2015-2019
9.5.3.2 R&D Expenses, 2015-2019
9.5.3.3 Gross Profit, 2015-2019
9.5.3.4 Net Income, 2015-2019
9.5.3.5 EBDITA, 2015-2019
9.5.4 Product Benchmarking
9.5.5 Recent Developments, 2017-2020
9.6 Dako (Agilent Technologies)
9.6.1 Company Snapshot
9.6.2 Company Overview
9.6.3 Financial Analysis
9.6.3.1 Net Revenue, 2015-2020
9.6.3.2 R&D Expenses, 2015-2020
9.6.3.3 Gross Profit, 2015-2020
9.6.3.4 Net Income, 2015-2020
9.6.3.5 EBDITA, 2015-2020
9.6.4 Product Benchmarking
9.6.5 Recent Developments, 2017-2020
9.7 Danaher
9.7.1 Company Snapshot
9.7.2 Company Overview
9.7.3 Financial Analysis
9.7.3.1 Net Revenue, 2015-2019
9.7.3.2 R&D Expenses, 2015-2019
9.7.3.3 Gross Profit, 2015-2019
9.7.3.4 Net Income, 2015-2019
9.7.3.5 EBDITA, 2015-2019
9.7.4 Product Benchmarking
9.8 FOUNDATION MEDICINE, INC.
9.8.1 Company Snapshot
9.8.2 Company Overview
9.8.3 Product Benchmarking
9.8.4 Recent Developments, 2017-2020
9.9 Genomic Health (Exact Sciences Corporation)
9.9.1 Company Snapshot
9.9.2 Company Overview
9.9.3 Financial Analysis
9.9.3.1 Net Revenue, 2015-2019
9.9.3.2 R&D Expenses, 2015-2019
9.9.3.3 Gross Profit, 2015-2019
9.9.3.4 Net Income, 2015-2019
9.9.3.5 EBDITA, 2015-2019
9.9.4 Product Benchmarking
9.9.5 Recent Developments, 2017-2020
9.10 Hologic, Inc.
9.10.1 Company Snapshot
9.10.2 Company Overview
9.10.3 Financial Analysis
9.10.3.1 Net Revenue, 2015-2020
9.10.3.2 R&D Expenses, 2015-2020
9.10.3.3 Gross Profit, 2015-2020
9.10.3.4 Net Income, 2015-2020
9.10.3.5 EBDITA, 2015-2020
9.10.4 Product Benchmarking
9.10.5 Recent Developments, 2017-2020
9.11 Illumina, Inc.
9.11.1 Company Snapshot
9.11.2 Company Overview
9.11.3 Financial Analysis
9.11.3.1 Net Revenue, 2015-2019
9.11.3.2 R&D Expenses, 2015-2019
9.11.3.3 Gross Profit, 2015-2019
9.11.3.4 Net Income, 2015-2019
9.11.3.5 EBDITA, 2015-2019
9.11.4 Product Benchmarking
9.11.5 Recent Developments, 2017-2020
9.12 HTG Molecular Diagnostics, Inc.
9.12.1 Company Snapshot
9.12.2 Company Overview
9.12.3 Financial Analysis
9.12.3.1 Net Revenue, 2015-2019
9.12.3.2 R&D Expenses, 2015-2019
9.12.3.3 Gross Profit, 2015-2019
9.12.3.4 Net Income, 2015-2019
9.12.3.5 EBDITA, 2015-2019
9.12.4 Product Benchmarking
9.12.5 Recent Developments, 2017-2020
9.13 Grifols, S.A.
9.13.1 Company Snapshot
9.13.2 Company Overview
9.13.3 Financial Analysis
9.13.3.1 Net Revenue, 2015-2019
9.13.3.2 R&D Expenses, 2015-2019
9.13.3.3 Gross Profit, 2015-2019
9.13.3.4 Net Income, 2015-2019
9.13.3.5 EBDITA, 2015-2019
9.13.4 Product Benchmarking
9.13.5 Recent Developments, 2017-2020
9.14 QIAGEN
9.14.1 Company Snapshot
9.14.2 Company Overview
9.14.3 Financial Analysis
9.14.3.1 Net Revenue, 2015-2019
9.14.3.2 R&D Expenses, 2015-2019
9.14.3.3 Gross Profit, 2015-2019
9.14.3.4 Net Income, 2015-2019
9.14.3.5 EBDITA, 2015-2019
9.14.4 Product Benchmarking
9.14.5 Recent Developments, 2017-2020
9.15 Siemens Healthcare GmbH
9.15.1 Company Snapshot
9.15.2 Company Overview
9.15.3 Financial Analysis
9.15.3.1 Net Revenue, 2015-2020
9.15.3.2 R&D Expenses, 2015-2020
9.15.3.3 Gross Profit, 2015-2020
9.15.3.4 Net Income, 2015-2020
9.15.3.5 EBDITA, 2015-2020
9.15.4 Product Benchmarking
9.16 Sysmex Corporation
9.16.1 Company Snapshot
9.16.2 Company Overview
9.16.3 Financial Analysis
9.16.3.1 Net Revenue, 2016-2020
9.16.3.2 Gross Profit, 2016-2020
9.16.3.3 Net Income, 2016-2020
9.16.3.4 EBDITA, 2016-2020
9.16.4 Product Benchmarking
9.16.5 Recent Developments, 2017-2020
10 Conclusion and Recommendations
10.1 Concluding Remarks
10.2 Recommendations
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer